

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

25048-20

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/009854INTERNATIONAL APPLICATION NO.
PCT/EP00/05254INTERNATIONAL FILING DATE
07 JUNE 2000 (07.06.00)PRIORITY DATE CLAIMED
10 JUNE 1999 (10.06.99)

TITLE OF INVENTION

CARRIER-DRUG CONJUGATE

APPLICANT(S) FOR DO/EO/US

KRATZ, Felix

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). (unsigned)
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Applicant is entitled to small entity status.

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/009854)		INTERNATIONAL APPLICATION NO. PCT/EP00/05254		ATTORNEY'S DOCKET NUMBER 25048-20	
---	--	--	--	-----------------------------------	--

24. The following fees are submitted:


BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/>	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1000.00			
<input checked="" type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$860.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$710.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	17 - 20 =	0	x \$18.00	\$0.00	
Independent claims	3 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$430.00	
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be: refunded	\$
				charged	\$

- a. ☒ A check in the amount of \$430.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 08-0719 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

John B. Hardaway, III
 NEXSEN PRUET JACOBS & POLLARD, LLC
 P.O. Box 10107
 Greenville, South Carolina 29603
 United States of America


 SIGNATURE

J. Herbert O'Toole

NAME

31,404

REGISTRATION NUMBER

10 December 2001

DATE

BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FILED UNDER THE PATENT COOPERATION TREATY
U.S NATIONAL PHASE OF PROSECUTION
EO/US

APPLICANT: KRATZ, Felix
INTERNATIONAL APPL. NO.: PCT/EP00/05254
INTERNATIONAL FILING DATE: 07 JUNE 2000 (07.06.00)
TITLE: CARRIER-DRUG CONJUGATE
ATTORNEY DOCKET NO.: 25048-20

Assistant Commissioner for Patents
Box PCT
Washington, DC 20231
ATTN: EO/US

PRELIMINARY AMENDMENT

Dear Sir:


Prior to calculating the filing fee and prior to examination of the U.S national entry application arising from the referenced international application, please enter the following amendment on the appended pages.

Please cancel claims 1-17.

Please enter new claims 18-34.

A copy of the translated Article 34 amendment is included for the record only. The claims therein are hereby superceded by the new claims 18-34.

Respectfully submitted,



J. Herbert O'Toole
Agent/Attorney for Applicant

Date: 10 December 2001

Claims

18. (New) A carrier-drug conjugate comprising:

a carrier which comprises a polypeptide sequence having at least one reducible cystein group;

a drug moiety consisting essentially of a compound selected from the group consisting of pharmaceuticals and diagnostic compounds;

a spacer molecule; and

a thiol binding group;

wherein at least one of the spacer molecule(s), the linkage between spacer molecule and drug moiety and the linkage between spacer molecule and thiol binding group is cleavable hydrolytically or enzymatically, and

wherein at least 0.7 mol of drug is bound per mole of reducible cystein group through said thiol binding group.

19. (New) A carrier-drug conjugate according to claim 18 wherein the carrier is albumin.

20. (New) A carrier-drug conjugate according to claim 18 wherein at least one of said spacer molecule(s) and said linkage contains a peptide bond.

21. (New) A carrier-drug conjugate according to claim 20 which is cleavable by a protease.

22. (New) A carrier-drug conjugate according to claim 18 wherein at least one of said spacer molecule(s) and said linkage is hydrolysable in an acidic medium.

23. (New) A carrier-drug conjugate according to claim 18 wherein said pharmaceutical is selected from the group consisting of cytostatics, cytokines, immunosuppressants, antirheumatics, antipyretics, antiinflammatories, antibiotics, analgesics,

virostatics and anti-fungals.

24. (New) A carrier-drug conjugate according to Claim 23, wherein the cytostatic pharmaceutical is selected from the group consisting of the anthracyclines, the N-nitrosoureas, alkylating agents, purine or pyrimidine antagonists, folic acid antagonists, taxanes, camptothecins, podophyllotoxin derivatives, Vinca alkaloids, calicheamicins, maytansinoids or *cis*-configured platinum(II) complexes.

25. (New) A carrier-drug conjugate according to Claim 18 wherein the diagnostically active substance contains at least one substance selected from the group consisting of radionuclides, one or a plurality of ligands containing radionuclides, positron emitters, NMR contrast media, and fluorescing compound(s) and contrast media functional in the near IR region.

26. (New) A carrier-drug conjugate according to one of Claim 18, in which the thiol-binding group contains a maleinimide group, a haloacetamide group, a haloacetate group, a pyridyldithio group, a vinylcarbonyl group, an aziridine group, a disulfide group or an acetylene group, which may be substituted or unsubstituted.

27. (New) A carrier-drug conjugate according to Claim 18 wherein said spacer molecule is selected from the group consisting of substituted or unsubstituted, branched-chain or straight-chain aliphatic alkyl groups having 1 to 12 carbon atoms, substituted or unsubstituted aryl groups and aliphatic carbon rings having 3 to 12 carbon atoms.

28. (New) A method for the preparation of a carrier-drug conjugate comprising

(i) treating a carrier with a reducing agent so that at least 0.7 mol of cysteine SH groups is present in the carrier per mol of reducible cysteine

group; and

- (ii) coupling a drug to said cysteine SH groups in said carrier via the thiol-binding group.

29. (New) A method according to Claim 28, wherein said reducing agent is selected from a group consisting of dithiothreitol, dithioerythritol or mercaptoethanol.

30. (New) A method according to Claim 28 wherein said conjugate prepared exhibits a purity higher than 95%.

31. (New) A medicament containing the conjugate according to Claim 18 and, optionally, a pharmaceutically compatible excipient.

32. (New) A medicament according to Claim 31 for the treatment of cancer, autoimmune disorders, acute or chronically inflammatory diseases and diseases that are caused by infectious agents selected from the

group consisting of viruses and microorganisms in mammals in need thereof.

33. (New) A diagnostic kit comprising a carrier-drug conjugate according to Claim 18.

34. (New) A diagnostic kit according to Claim 33 for the detection of diseases selected from a group consisting of cancer, autoimmune disorders, acute or chronically inflammatory diseases, diseases that are caused by infectious agents selected from the group consisting of viruses and microorganisms.

4/pst

CARRIER-DRUG CONJUGATE

[0001] This invention relates to carrier-drug conjugates as well as methods for their preparation and medicaments that contain the conjugates.

[0002] Many of the drugs now used are low-molecular-weight compounds and exhibit a high plasma clearance or total body clearance after systemic administration. Furthermore, they penetrate into the tissue structures of the body by diffusion processes and exhibit, as a rule, a uniform biodistribution. The two properties result in only small quantities of the drug reaching the place of action, and the drug brings about side effects on the healthy tissues of the body because of its distribution. These disadvantages are especially marked in the case of such drugs as possess a high cytotoxic potential, such as cytostatics or immunosuppressants.

[0003] New derivatives or formulations that permit a more selective therapy are therefore sought. To this end, chemoimmunoconjugates, or protein conjugates or polymer conjugates made up of a suitable carrier substance and a drug, are being developed.

[0004] With regard to the related art in this area, mention should be made of polymer conjugates in which cytostatics are coupled to serum proteins, antibodies, growth factors, hormone-like or peptide-like structures, or synthetic

polymers (Mägerstädt, M., Antibody Conjugates and Malignant Disease, Library of Congress, 1990; Seymour, L. W., *Crit. Rev. Ther. Drug Carrier Sys.* (1992), 9, 135-187; Maeda, H., and Matsumura, Y., *Crit. Rev. Ther. Drug Carrier Sys.* (1989), 6, 193-210).

[0005] DE-A-41 22 210 describes conjugates of tumor-active compounds with albumin, the tumor-active compound being activated with N-hydroxysuccinimide and carbodiimide and the mixture so obtained being coupled directly to the carrier protein. The disadvantages of these conjugates are, among other things, that they cannot be obtained in the requisite high purity, the native structure of the albumin often does not remain intact on account of the preparation method, and the stoichiometric ratio of drug to albumin is inconstant and poorly reproducible. Furthermore, these conjugates do not allow of being released in suitable fashion in the target tissue or in the target cells.

[0006] It is therefore an object of the present invention to provide new carrier-drug conjugates that overcome the disadvantages of the conjugates known heretofore.

[0007] This object is achieved through the embodiments of the present invention characterized in the Claims.

[0008] In particular, there is provided a carrier-drug conjugate made up of a carrier, which contains a polypeptide

sequence having one or a plurality of cysteine groups, and a drug, which contains a pharmaceutically and/or diagnostically active substance, a spacer molecule, and a thiol-binding group, more than 0.7 mol, preferably at least 0.9 mol, of drug per mol of cysteine group being bound to the carrier via the thiol-binding group. The expression "pharmaceutically active substance" means that the substance in question brings about a pharmacological effect either by itself or after its conversion by metabolism in the organism in question, and thus also includes the derivatives resulting from these conversions. Naturally, the pharmaceutically active substance can exhibit a single (for example as a cytostatic only) or a broad pharmacological action spectrum (for example as a cytostatic and as an antiphlogistic). The expression "diagnostically active substance" means that the substance in question can be detected, preferably also quantified, in the organism or parts thereof, such as for example cells and/or fluids, such as for example the serum, through suitable chemical and/or physical measurement methods.


[0009] The release of the pharmaceutically active substance is preferred because, as a rule, the low-molecular-weight active substance must interact with the target molecule in order to bring its pharmacological effectiveness into play. In the case of diagnostically active substances, as a rule,

release of the diagnostic drug bound to the carrier molecule is not necessary but nevertheless can take place. According to the invention, therefore, a diagnostically active substance in particular can additionally be bound to the spacer molecule via a bond not cleavable in the body or directly to the carrier molecule-binding group.

[0010] According to a preferred embodiment of the conjugate according to the invention, the carrier is native or recombinant albumin.

[0011] The drug or the drug derivative in the conjugate according to the invention can be represented, for example, by the following scheme (AS, pharmaceutically and/or diagnostically active substance; SM, spacer molecule; TG, thiol-binding group):

[0012] The conjugate according to the invention represents a transport and/or depot form of the pharmaceutically



and/or diagnostically active substance, which thus reaches the target cells or the target tissue of the drug in targeted manner or in metered form. In contrast to the previously known conjugates, the conjugates of the present invention can be obtained in a high purity, the native structure of the carrier remains intact, and the stoichiometric ratio of drug to carrier is constant and reproducible.

202000-1585000
[0013] In contrast to the albumin-cytostatic conjugates described in DE-A-41 22'210, the conjugate according to the invention further has the advantage that a spacer molecule is present between the pharmaceutically and/or diagnostically active substance and the thiol-binding group, which spacer molecule is tailored such that the pharmaceutically and/or diagnostically active substance or a corresponding active derivative thereof can be released hydrolytically and/or in pH-dependent fashion and/or enzymatically in the target tissue or in the target cells.

[0014] Carriers such as for example albumin or its drug conjugates exhibit a markedly long half-life in the systemic circulation (up to 19 days--Peters, T., Jr. (1985): Serum Albumin, *Adv. Protein. Chem.* 37, 161-245). Because of an elevated permeability of vessel walls of the malignant, infected or inflamed tissue for macromolecules, the carrier such as for example serum albumin passes preferentially into the target tissue (Maeda, H., and Matsumura, Y., *Crit. Rev. Ther. Drug Carrier Sys.* (1989), 6, 193-210). As a result, an active substance coupled to a carrier, for example albumin, can reach the place of action in more targeted fashion. Furthermore, the carrier-drug conjugate according to the invention prevents the pharmaceutically and/or diagnostically active substance from diffusing into healthy tissue structures of the body or from

being eliminated via the kidney or injuring the kidney as much as the unbound pharmaceutically and/or diagnostically active substance. As a result, the pharmacokinetic profile of the pharmaceutically and/or diagnostically active substance is modified and improved, because the action of the pharmaceutically and/or diagnostically active substance is increased by a buildup at the place of action and, at the same time, the toxic effects on healthy systems of the body are diminished.

[0015] The conjugate of the present invention has excellent solubility in water. Furthermore, the conjugate according to the invention shows, *in vivo*, for example, an improved antitumoral effectiveness in comparison to the unbound pharmaceutically and/or diagnostically active substance.

[0016] According to a preferred embodiment of the conjugate according to the invention, the spacer molecule and/or the linkage between the pharmaceutically and/or diagnostically active substance and the spacer molecule and/or the linkage between the thiol-binding group and the spacer molecule is cleavable hydrolytically and/or in pH-dependent fashion and/or enzymatically. Preferably, the spacer molecule and/or the linkage between the pharmaceutically and/or diagnostically active substance and the spacer molecule and/or the linkage between the thiol-binding group and the spacer molecule contains

at least one acid-labile bond. Examples of acid-labile bonds are ester, acetal, ketal, imine, hydrazone, carboxylhydrazone and sulfonylhydrazone bonds and bonds containing a trityl group. Bonds cleaved by hydrolysis with release of the pharmaceutically and/or diagnostically active substance are, for example, ester bonds or metal-complex compounds, such as are present in platinum-dicarboxylate complexes, where a diaminediaquo-platinum(II) complex is liberated. Examples of bonds not cleavable in the body, which may be present for example in the case of linkage to a diagnostically active substance, are amide bonds, saturated and unsaturated carbon-carbon bonds or bonds between carbon and a heteroatom, -C-X-, where X is preferably O, N, S or P.

[0017] According to a further embodiment of the conjugate according to the invention, the spacer molecule and/or the linkage between the pharmaceutically and/or diagnostically active substance and the spacer molecule and/or the linkage between the thiol-binding group and the spacer molecule contains at least one peptide bond. The peptide bond preferably lies within a peptide sequence that contains at least one cleavage sequence of a protease. The at least one peptide bond can therefore be implemented by the insertion of a peptide sequence into the spacer molecule and/or into the linkage between the pharmaceutically and/or diagnostically active substance and the

spacer molecule and/or into the linkage between the thiol-binding group and the spacer molecule; that is, the linkage in question is a peptide bond and is preferably made up of about 1 to 30 amino acids. The peptide sequence is thus preferably tailored to the substrate specificity of certain of the body's own enzymes or of enzymes that occur in or are formed by microorganisms. In this way, the peptide sequence or a part of this sequence is recognized in the body by the enzymes and the peptide is cleaved.

[0018] The enzymes are, for example, proteases and peptidases, for example matrix metalloproteases (MMP), cysteine proteases, serine proteases and plasmin activators, which are formed or activated in intensified manner in diseases such as rheumatoid arthritis or cancer, leading to excessive tissue degradation, inflammations and metastasis. Target enzymes are in particular MMP 2, MMP 3 and MMP 9, which take part in the cited pathological processes as proteases (Vassalli, J., and Pepper, M. S. (1994), *Nature* 370, 14-15; Brown, P. D. (1995), *Advan. Enzyme Regul.* 35, 291-301).

[0019] Further proteases that represent target enzymes for conjugates of the present invention are cathepsins, in particular cathepsin B and H, which have been identified as key enzymes in inflammatory and malignant diseases (T. T. Lah et al. (1998), *Biol. Chem.* 379, 125-301).

20200504-030702


[0020] According to a further embodiment of the conjugate according to the invention, the spacer molecule and/or the linkage between the pharmaceutically and/or diagnostically active substance and the spacer molecule and/or the linkage between the thiol-binding group and the spacer molecule contains at least one bond that is enzymatically cleavable but is not made up of a peptide bond. Examples are carbamate bonds, in which the active substance or a derivative of the active substance is released by cleavage with disease-specific enzymes, for example glutathione S-transferases, glucuronidases, galactosidases. It is also immediately possible that an enzymatically cleavable bond is built up from a peptide sequence and one of the aforementioned bonds that is not a peptide bond.

[0021] All the cited types of bond--hydrolytically cleavable bond, acid-labile bond, peptide bond, enzymatically cleavable bond not containing a peptide bond, and bond built up from a peptide sequence and a non-peptide bond--guarantee that the pharmaceutically and/or diagnostically active substance or a correspondingly active derivative is cleaved extracellularly and/or intracellularly at the place of action and the substance can bring its pharmaceutical and/or diagnostic action into play.


[0022] According to a preferred embodiment, the pharmaceutically active substance is a cytostatic, a cytokine,

10009334-030702


an immunosuppressant, an antirheumatic, an antiphlogistic, an antibiotic, an analgesic, a virostatic or an antimycotic. Especially suitable cytostatics of the conjugates of the present invention are the N-nitrosoureas such as nimustine, the anthracyclines doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone and ametantrone as well as related derivatives; the alkylating agents chlorambucil, bendamustine, melphalan and oxazaphosphorines as well as related derivatives; the antimetabolites, for example purine antagonists or pyrimidine antagonists, and folic acid antagonists such as methotrexate, 5-fluorouracil, 2'-deoxy-5-fluorouridine and thioguanine as well as related derivatives; the taxanes paclitaxel and docetaxel as well as related derivatives; the camptothecins topotecan, irinotecan, 9-aminocamptothecin and camptothecin as well as related derivatives; the podophyllotoxin derivatives etoposide, teniposide and mitopodozide as well as related derivatives; the Vinca alkaloids vinblastine, vincristine, vindesine and vinorelbine as well as related derivatives; calicheamicins; maytansinoids; and *cis*-configured platinum(II) complexes of the general formulas I to XII:



Formula I




Formula II




Formula III

Formula IV




Formula VI


Formula V




Formula VII




Formula IX






Formula X



Formula XI



Formula XII



where X is the spacer molecule or the thiol-binding group.

[0023] Especially suitable cytokines in conjugates of the present invention are, for example, interleukin 2, interferon α -2a, interferon α -2b, interferon β -1a, interferon β -1b, interferon γ -1b and related derivatives. The cytokines used are, as a rule, medicaments prepared using genetic engineering.

[0024] Especially suitable immunosuppressants in

conjugates of the present invention are, for example, cyclosporin A, FK 506 and related derivatives.

[0025] Especially suitable antirheumatics in conjugates of the present invention are, for example, methotrexate, sulfasalazine, chloroquine and related derivatives.

[0026] Especially suitable antiphlogistics and/or analgesics in conjugates of the present invention are, for example, salicylic acid derivatives such as for example acetylsalicylic acid and related derivatives; drug derivatives having an acetic or propionic acid group such as diclofenac or, respectively, indomethacin or ibuprofen or, respectively, naproxen; and aminophenol derivatives such as for example paracetamol.

[0027] Especially suitable antimycotics in conjugates of the present invention are, for example, amphotericin B and related derivatives.

[0028] Preferred virostatics in conjugates of the present invention are, for example, nucleoside analogs such as acyclovir, ganciclovir, idoxuridine, ribavirin, vidaribine, zidovudine, didanosine and 2',3'-dideoxycytidine (ddC) and related derivatives, as well as amantadine.

[0029] Preferred antibiotics in the conjugate according to the invention are sulfonamides, for example sulfanilamide, sulfacarbamide and

10009854-130702
202504150900T

sulfamethoxydiazine and related derivatives; penicillins, for example 6-aminopenicillanic acid, penicillin G as well as penicillin V and related derivatives; isoxazolympenicillins such as oxacillin, cloxacillin and flucloxacillin as well as related derivatives; α -substituted benzylpenicillins such as ampicillin, carbenicillin, pivampicillin, amoxicillin and related derivatives; acylaminopenicillins, for example mezlocillin, azlocillin, piperacillin, apalcillin and related derivatives; amidinopenicillins, for example mecillinam; atypical β -lactams such as imipenam and aztreonam; cephalosporins, for example cephalixin, cefradin, cefaclor, cefadroxil, cefixime, cefpodoxime, cefazolin, cefazedone, cefuroxime, cefamandole, cefotiam, cefoxitin, cefotetan, cefmetazole, latamoxef, cefotaxime, ceftriaxone, ceftizoxime, cefmonoxime, ceftazidime, cefsulodin and cefoperazone as well as related derivatives; tetracyclines such as tetracycline, chlorotetracycline, oxytetracycline, demeclocycline, rolitetracycline, doxycycline, minocycline and related derivatives; chloramphenicols such as chloramphenicol and thiamphenicol as well as related derivatives; gyrase inhibitors, for example nalidixic acid, pipemidic acid, norfloxacin, ofloxacin, ciprofloxacin and enoxacin as well as related derivatives; and antituberculotics such as isoniazid and related derivatives.

[0030] Of course, a single drug species (for example a

drug with a cytostatic as pharmaceutically active substance) or various drug species (for example a plurality of distinct cytostatics or a cytostatic and an antiphlogistic, etc., as pharmaceutically active substance) can be present in combined form per mole in the conjugate according to the invention.

[0031] According to a further preferred embodiment of the conjugate according to the invention, the spacer molecule contains a substituted or unsubstituted, branched-chain or straight-chain aliphatic alkyl group with 1 to 12 carbon atoms and/or at least one substituted or unsubstituted aryl group and/or an aliphatic carbon ring with 3 to 12 carbon atoms. The aliphatic alkyl group preferably contains 1 to 20 carbon atoms, which may in part be replaced by oxygen atoms in order, for example, to increase the solubility in water, such groups preferably being derived from an oligoethylene oxide or oligopropylene oxide chain. Especially suitable groups that are derived from oligoethylene oxide or oligopropylene oxide chains include, for example, diethylene glycol chains, triethylene glycol chains and dipropylene glycol chains. A preferred aryl group is an unsubstituted or substituted phenyl group in which, likewise, one or a plurality of carbon atoms may be replaced by heteroatoms. Preferred substituents of the aliphatic alkyl group or of the aryl group are hydrophilic groups such as sulfonic acid groups, aminoalkyl groups and hydroxy groups.

20200914 15:00:00

[0032] Preferred diagnostically active substances of the conjugate according to the invention include, for example, one or a plurality of radionuclides; one or a plurality of ligands containing radionuclides, preferably complexing such radionuclides; one or a plurality of positron emitters; one or a plurality of NMR contrast media; one or a plurality of fluorescing compound(s); or one or a plurality of contrast media in the near IR region.

[0033] In a further preferred embodiment of the conjugate according to the invention, the thiol-binding group contains a maleinimide group, a haloacetamide group, a haloacetate group, a pyridyldithio group, a vinylcarbonyl group, an aziridine group, a disulfide group or an acetylene group, which are substituted if appropriate.


[0034] The drug or drug derivative of the conjugates according to the invention can be prepared according to one of the following general descriptions, depending on what functional group is present.

[0035] Drugs or drug derivatives, having an HOOC group, of the conjugates according to the invention can be derivatized, for example, in the following way:



[0036] Esterification here is effected with methods known in the related art.

[0037] It is further possible to convert the HOOC group to a hydrazide group, for example by reaction with tert-alkylcarbazates followed by cleavage with acids (described in DE-A-196 36 889), and to react the drug, having a hydrazide group, with a group containing a carbonyl component and made up of the thiol-binding group and the spacer molecule, as is



R = H, alkyl, phenyl, substituted phenyl
described, among others, in DE-A-196 36 889:

[0038] Drugs or drug derivatives, having an H₂N group, of the conjugates according to the invention can be derivatized, for example, in the following way:





R = H, alkyl, phenyl, substituted phenyl

[0039] The reaction to the imine derivatives here is effected with methods known in the related art.

[0040] Drugs or drug derivatives, having an HO group, of the conjugates according to the invention can be derivatized, for example, in the following way:





where R is an aliphatic carbon chain and/or an aliphatic carbon ring and/or an aromatic and $\text{R}_1 = \text{H}$, alkyl, an unsubstituted phenyl group or a substituted phenyl group. R preferably contains 1 to 12 carbon atoms, which may likewise be substituted, for example by hydrophilic groups such as sulfonic acid groups, aminoalkyl groups or hydroxyl groups. The aromatic is preferably a benzene ring, which may likewise be substituted. Preferred substituents are, for example, the above-named hydrophilic groups.

[0045] The carbonyl component can furthermore be introduced by other chemical reactions, for example by electrophilic substitution on the HO or NH_2 group of the active substance with a suitable carbonyl component.




[0046] The drugs derivatized in this way, which now have a carbonyl component, are converted to the corresponding carboxylhydrazone, sulfonylhydrazone, hydrazone or imine derivatives in a fashion analogous to the above-described methods with carrier molecule-binding spacer molecules having an amino group, hydrazide group or hydrazine group. The cleavage of

these acid-labile bonds afterward leads to a release of derivatized pharmaceutically and/or diagnostically active substance having a carbonyl component.









[0047] The groups that are made up of the thiol-binding group and the spacer molecule can be prepared, for example, according to methods that are described in, among others, DE-A-196 36 889, U. Beyer et al. 1997 (*Chemical Monthly*, 128, 91, 1997), R. S. Greenfield et al., 1990 (*Cancer Res.*, 50, 6600, 1990), T. Kaneko et al., 1991 (*Bioconjugate Chem.*, 2, 133, 1991), *Bioconjugate Techniques* (G. T. Hermanson, Academic Press, 1996), or in U.S. Patent No. 4,251,445.

[0048] Drugs or drug derivatives, containing a peptide bond, of the conjugates according to the invention can be prepared, for example, by reacting a peptide that is made up of 2 to about 30 amino acids with a thiol-binding compound, so that a thiol-binding group is introduced directly or via a spacer molecule at the N-terminal end of the peptide. The synthesis of such carrier molecule-binding peptide derivatives is preferably effected by a solid-phase synthesis known to one skilled in the art, a carboxylic acid-bearing, carrier molecule-binding spacer molecule, for example a maleinimide carboxylic acid, being bound by peptide coupling to the N-terminal end of the peptide in the last step of peptide assembly and the carrier molecule-binding peptide then being split off from the solid phase.

[0049] In the presence of a condensation agent such as for example N,N'-dicyclohexylcarbodiimide (DCC) or N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide methyl-p-toluenesulfonate (CMC) or 1-benzotriazolyloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) or benzotriazolyl-N,N,N',N'-tetramethyluronium hexafluorophosphate, and if appropriate with the addition of N-hydroxysuccinimide or of a water-soluble N-hydroxysuccinimide such as for example N-hydroxysuccinimide-3-sulfonic acid sodium salt, or 1-hydroxybenzotriazole, and/or in the presence of a base, for example N-methylmorpholine or triethylamine, the peptide derivatives so obtained can be reacted to the corresponding thiol-binding drug-peptide derivatives with drugs or drug derivatives that have an H₂N or HO group:



[0050] It is further possible, via the HOOC group of the drugs of the conjugates according to the invention, to introduce an H₂N or HO group, for example by derivatization via the α-amino group of the amino acids lysine, serine or threonine or with a diamino compound of the general formula H₂N-(CH₂)_n-NH₂ or an alcoholamine of the general formula H₂N-(CH₂)_n-OH with n = 1 to 12, and then to react these derivatives with the above-cited peptide derivatives to the corresponding thiol-binding drug-peptide derivatives:



A = lysine, serine or threonine

[0051] The substrate specificity of target enzymes such as for example of MMP 2, MMP 3, MMP 9, cathepsin B and H is known (Netzel-Arnett et al. (1993), *Biochemistry* 32, 6427-6432, Shuja, S., Sheahan, K., and Murnane, M. J. (1991), *Int. J. Cancer* 49, 341-346, Lah, T. T., and Kos, J. (1998), *Biol. Chem.*

379, 125-130).

[0052] For example, octapeptides (P_4 - P'_4) for MMP 2 and MMP 9 have been identified (see Table 1), which octapeptides simulate the cleavage sequence of the collagen chain and are cleaved with particular efficiency by MMP 2 and 9 (in what follows, amino acids are abbreviated in accordance with the international three-letter code):

Table 1:

Peptide							
P_4	P_3	P_2	P_1	P'_1	P'_2	P'_3	P'_4

Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln							
Gly-Pro-Gln-Gly--Ile-Trp-Gly-Gln							
(Netzel-Arnett et al., <i>Biochemistry</i> 32, 1993, 6427-6432)							

[0053] The peptides are enzymatically cleaved exclusively at the P_1 - P'_1 bond.

[0054] Furthermore, in the case of cathepsin B, substrate-specific peptides are known with the sequence - Gly-Phe-Leu-Gly-, -Gly-Phe-Ala-Leu-, -Ala-Leu-Ala-Leu-, -Arg-Arg- or -Phe-Lys- (Werle, B., Ebert, E., Klein, W., and Spiess, E. (1995), *Biol. Chem. Hoppe-Seyler* 376, 157-164;

Ulricht, B., Spiess, E., Schwartz-Albiez, R., and Ebert, W.
(1995), *Biol. Chem. Hoppe-Seyler* 376, 404-414).

[0055] The peptide sequence that contains intended peptide cleavage points relevant for the target enzyme can also be constructed such that the intended peptide cleavage point is repeated a plurality of times, for example by:

-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln

or

-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-


or a repetitive peptide sequence can be integrated that increases the distance between the thiol-binding group and the relevant intended peptide cleavage point, as for example by:

-(Gly)_n-Phe-Lys-Phe-Lys-

with, preferably, $n = 2$ to 20 , more preferably $n \leq 12$.

[0056] An important feature of this embodiment of the conjugate according to the invention is that the intended peptide cleavage point relevant for the target enzyme in question is present at least once in an oligopeptide made up of roughly 1 to 30 amino acids. The above-cited oligopeptides are representative examples for the enzymatically cleavable bond in the conjugates according to the invention and do not restrict the invention.

[0057] Drugs or drug derivatives, containing a cytokine, of the conjugates according to the invention can be prepared,



for example, by reacting the cytokine with a spacer molecule containing a thiol-binding group, which spacer molecule exhibits a carboxylic acid or an activated carboxylic acid:

[0058] If the spacer molecule exhibits an N-hydroxysuccinimide ester group (N-hydroxysuccinimide or N-hydroxysuccinimide-3-sulfonic acid sodium salt), it is reacted directly with the cytokine. The reaction of the cytokine with a spacer molecule containing a thiol-binding group, which spacer molecule exhibits a carboxylic acid, to the corresponding thiol-binding derivatives takes place in the presence of a condensation agent, such as for example N,N'-dicyclohexylcarbodiimide (DCC) or N-cyclohexyl-N'-(2-morpholinoethyl)-carbodiimide methyl-*p*-toluene sulfonate (CMC), and if appropriate with the addition of N-hydroxysuccinimide or N-hydroxysuccinimide-3-sulfonic acid sodium salt. As a rule, the cytokines derivatized in this way are purified with the aid of gel chromatography. The above-described reactions are well known to a person skilled in the art (see, e.g., Bioconjugate Techniques, G. T. Hermanson, Academic Press, 1996).

[0059] The above-described drugs or drug derivatives are coupled to a carrier containing a polypeptide sequence with one or a plurality of cysteine groups, such as for example native or

20200904-030702 recombina nt albumin, so that more than 0.7 mol, preferably at least 0.9 mol, of 'drug' per mol of cysteine group is bound to the carrier via the thiol-binding group. If the polypeptide sequence of the carrier contains n (for example 3) cysteine groups, this means that 1 mol of this carrier contains n (for example 3) mol of cysteine groups, and thus a maximum of n (for example 3) mol of drug can be present bound to the carrier per mol of the corresponding conjugate. In the conjugate according to the invention, therefore, 100% of the cysteine groups present in the carrier are ideally bound with a drug via the thiol-binding group.

[0060] A further embodiment of the present invention thus relates to a method for the preparation of a conjugate as defined above, including

- (i) treatment of the carrier with a reducing agent so that more than 0.7 mol, preferably at least 0.9 mol, of cysteine SH groups is present in the carrier per mol of cysteine group and
- (ii) coupling of the drug to the cysteine SH groups in the carrier via the thiol-binding group.

[0061] In a preferred embodiment of the method according to the invention, the reducing agent used for the treatment of the carrier is dithiothreitol (DTT), dithioerythritol (DTE) or mercaptoethanol. The especially preferred reducing agent is DTT.

phosphate in a pH range of 5.0 to 8.0, preferably 6.0 to 7.0.

The reducing agent can be in excess; preferably the ratio of reducing agent to carrier is between 0.5:1 and 10:1. The reaction time is between 1 h and 96 h, preferably between 6 h and 24 h.

[0065] The carrier treated with the reducing agent is isolated, for example, by gel filtration (for example Sephadex® G10 or G25; solvent 0.004 M phosphate, 0.15 M NaCl, pH 7.4) or by ultrafiltration.

[0066] The concentration of carrier after gel filtration has been carried out is determined using the extinction coefficient at 280 nm; the number of HS groups inserted is determined with Ellmann's reagent at 412 nm. The carrier solution thus isolated can be used directly for the synthesis of the conjugates. It is also possible to concentrate the carrier solution with a commercially available concentrator or to lyophilize it. The isolated carrier solution or the lyophilizate can be stored in the temperature range of -78 to +30 °C.

[0067] The coupling of the above-described drug derivatives to the carrier takes place, for example, at room temperature. To the carrier, which is in a salt buffer (for example 0.15 M NaCl, pH 6.0 to 8.0), which was previously degassed if appropriate, there is added a roughly 1.1-fold to 10-fold excess of the drug prepared as described above (relative

to the number of HS groups present in the carrier), dissolved in a minimal quantity of solvent, for example DMF, dimethyl sulfoxide, water, salt buffer, ethanol, methanol, propylene glycol, glycerin, acetonitrile or THF (roughly 1 to 10% of the volume of the test portion of carrier). It is also possible to add the drug to the carrier solution as a solid. Furthermore, it may be advantageous to add an auxiliary agent, such as for example a fatty acid or a tryptophanate derivative, to the carrier solution. After a reaction time between 5 min and 48 h, the solution is centrifuged if necessary, and the carrier-drug conjugate formed is isolated by subsequent gel filtration (for example Sephadex® G10 or G25) in a salt buffer, such as for example 0.004 M phosphate, 0.15 M NaCl, pH 6.0 to 8.0.

[0068] The purity of the conjugate obtained can be verified, for example, by HPLC, for example by gel chromatography. In contrast to commercially available conjugates, the conjugates prepared according to a preferred embodiment of the method according to the invention exhibit a purity of more than 95%.

[0069] The solution of the conjugate so obtained can be concentrated with a commercially available concentrator. The conjugates can be stored in dissolved form at +1 to +30 °C or in frozen form at T = 0 °C to -78 °C. It is further possible to lyophilize the solution of the conjugates and to store the

lyophilizate at +30 ° to -78 °C.

[0070] A further embodiment of the present invention relates to a medicament containing a conjugate as defined above and, if appropriate, a pharmaceutically compatible carrier and/or auxiliary agent and/or a diluting agent. The medicament according to the invention can preferably be used for the treatment of cancer diseases, autoimmune diseases, acute or chronically inflammatory diseases, and diseases that are caused by viruses or microorganisms such as for example bacteria and/or fungi.

[0071] Yet a further embodiment of the present invention relates to a diagnostic kit including a conjugate as defined above. The diagnostic kit according to the invention can preferably be used for the detection of the diseases as above defined and/or for the detection of molecules of the carrier and/or their distribution in the body.

Brief Description of the Drawings

[0072] Fig. 1 (A) is an HPLC chromatogram of a conjugate according to the invention (A-DOXO-HYD-C). The plot shows the absorption at 495 nm versus the retention time in min. (B) is the corresponding HPLC chromatogram of commercially available native albumin (Immuno GmbH).

[0073] Fig. 2 shows HPLC chromatograms (gel chromatography, Biosil 250 SEC column, Biorad) of a conjugate

according to the invention (HSA-Cys³⁴-2), which is cleavable by the matrix metalloproteinase MMP 9. The absorption at 495 nm is also plotted versus the retention time in min. (A) Chromatogram of the conjugate HSA-Cys³⁴-2 before incubation with MMP 9 (t = 0). (B) Chromatogram of the conjugate HSA-Cys³⁴-2 after incubation with MMP 9 for 30 min (t = 30 min).

[0074] Fig. 3 shows the graphical representation of the weights and volumes of kidneys and renal tumors (A) as well as the lung weights and the number of pulmonary metastases (B) of mice in which a renal carcinoma was induced, and that were subjected to the cited treatments (control: no treatment; albumin control: native albumin; Doxo: doxorubicin; A-DOXO-HYD-C: conjugate according to the invention). For comparison, the data for mice not injected with tumor cells are also shown (no tumor).

[0075] The following example explains the present invention in greater detail without restricting it.

Example

Reaction of Human Serum Albumin (HSA) with Dithiothreitol (DTT)

[0076] The method for the treatment of HSA with a reducing agent is illustrated more exactly by the following example: 2.0 g of human serum albumin (10 mL of a 20% HSA solution, Pharma Dessau) is diluted with 10 mL of buffer A (0.004 M sodium phosphate, 0.15 M NaCl, pH 7.0) and added to 100


20200904 100954.030702
μL of a freshly prepared 0.036×10^{-2} M solution of DTT (5.55 mg of DTT dissolved in 100 μL of buffer A), and the reaction vessel, tightly sealed to exclude air, is shaken for 16 h at room temperature. The albumin solution is then purified by gel filtration (5.0 cm x 25.0 cm column, Sephadex® G25; solvent buffer 0.004 M sodium phosphate, 0.15 M NaCl, pH 7.4). The protein concentration after gel filtration was determined by photometry at 280 nm ($\epsilon(\text{HSA})_{280} = 35,700 \text{ M}^{-1} \text{ cm}^{-1}$, $c[\text{HSA}] \approx 3.1 \times 10^{-4} \text{ M}$), and the number of HS groups introduced was determined with Ellmann's reagent at 412 nm ($\epsilon_{412} = 13,600 \text{ M}^{-1} \text{ cm}^{-1}$, $c[\text{HS groups}] \approx 3.07 \times 10^{-4} \text{ M}$). In the HSA thus treated, there is accordingly 0.99 mol of free cysteine SH groups per mol of cysteine group. The treated HSA was concentrated to roughly $1.0 \times 10^{-3} \text{ M}$ (Centriprep-10®) and used directly for the coupling reaction, described in what follows, with a thiol-binding drug of the present invention.

Preparation of the Conjugate A-DOXO-HYD-C

According to the Invention

[0077] The HSA-doxorubicin conjugate (A-DOXO-HYD-C), made up of HSA treated with DTT in accordance with the above example, and a maleinimidophenylacetic acid hydrazone derivative of doxorubicin (DOXO-HYD), was further prepared in the following way.

[0078] Structure of DOXO-HYD:




[0079] 12 mL of the HSA test portion treated with DTT (sulfhydryl content of 0.99 mol per mol of HSA) was added to 0.6 mL of a solution of DOXO-HYD (Mr 807.8) in DMF (12.5 mg dissolved in 0.6 mL of DMF), and the reaction solution, sealed, was shaken for 18 h. The product HSA-doxorubicin conjugate was isolated using a Sephadex® G-25F column (column 5.0 cm x 25 cm) (retention volume 85-135 mL). The quantity of bound doxorubicin was determined with the help of the extinction coefficient of doxorubicin at 495 nm ($\epsilon_{495} = 10,650 \text{ M}^{-1} \text{ cm}^{-1}$ at pH 7.4). According to the determination, 0.97 mol of doxorubicin per mol of cysteine group in the HSA is bound to the HSA in this example.

[0080] *Methods:* FPLC for the preparation of the conjugates: P-500 pump, LCC 501 controller (Pharmacia) and LKB 2151 UV monitor. The protein concentration of the conjugate was determined photometrically and also by the BCA protein assay

(Pierce, U.S.A.).

[0081] The purity of the A-DOXO-HYD-C conjugate was checked by HPLC with the aid of an analytical column (Bio-Sil SEC 250 (300 mm x 7.8 mm), Bio-RAD (mobile phase, as a rule, 0.15 M NaCl, 0.01 M NaH₂PO₄, 5% CH₃CN, pH 7.0) at λ = 495 nm. The HPLC chromatograms for A-DOXO-HYD-C and of commercially available native albumin (Immuno GmbH) are presented in Fig. 1A (A-DOXO-HYD-C) and Fig. 1B (native albumin). It can be clearly seen that A-DOXO-HYD-C exhibits an excellent purity, comparable with the commercially available native albumin.

[0082] Structure of A-DOXO-HYD-C:




(HSA = human serum albumin)

Preparation of a Conjugate According to the Invention,
Containing HSA Treated with DTT and a Doxorubicin-Maleinimide-
Peptide Derivative Cleavable by MMP 9

[0083] The doxorubicin-maleinimide-peptide derivative
(2) was prepared in accordance with the following reaction

equation:




[0084] Here the octapeptide Gln-Gly-Ala-Ile-Gly-Leu-Pro-Gly derivatized with maleinimidoglycine 1 (Mr 848, prepared by solid-phase synthesis by Bachem AG, Switzerland) was reacted with doxorubicin according to the following method:

[0085] To a slightly turbid solution of 17.1 mg of doxorubicin in 3 mL of DMF there are added 25 mg of 1 (as the trifluoroacetate salt) dissolved in 500 μ L of DMF, 33.5 mg of O-benzotriazolyl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HPTU) dissolved in 200 μ L of DMF, 11.9 mg hydroxybenzotriazole hydrate dissolved in 100 μ L of DMF, and 16.2 μ L of N-methylmorpholine, and the charge is then agitated for 18 h at room temperature in darkness. DMF was removed under high vacuum, and the solid was taken up in 20 mL of methanol, filtered, and concentrated in vacuum to 1 mL. After purification with silica gel (acetate/methanol 2/1), 5 mg of 2 was obtained.

[0086] 3.0 mL of an HSA test portion treated with DTT (sulfhydryl content of 0.95 per HSA molecule, content of HS groups 1000 μ M) was added to a solution of 2 (Mr 1374) in DMF (5.1 mg dissolved in 250 μ L of DMF), and the reaction solution, sealed, was shaken for 30 min. The product albumin-doxorubicin conjugate was isolated using a Sephacryl® HR100 column (2.0 cm x 20 cm). In this way, the albumin conjugate (designated HSA-Cys³⁴-

2 in what follows) of the following structure was isolated (exhaustion factor approximately 0.9):



[0087] The peptide sequence Gln-Gly-Ala-Ile-Gly-Leu-Pro-Gly is recognized by the matrix metalloprotease MMP 9 and cleaved between isoleucine and glycine. This was shown by the following experiment: 200 μ L of a 100 μ M solution of HSA-Cys³⁴-2 was incubated for 30 minutes at 37 °C with trypsin/aprotinine-activated MMP 9 (2 mU, from Calbiochem, Germany). The liberation of DOXO-Gln-Gly-Ala-Ile due to cleavage with MMP 9 was confirmed by HPLC gel chromatography (Biosil 250 SEC column from Biorad, detection at λ = 495 nm) before incubation (t = 0, compare Fig. 2A) and after an incubation time of 30 minutes with activated MMP 9 (t = 30, compare Fig. 2B).

Biological Studies

[0088] As an example for the *in vivo* effectiveness of the conjugates according to the invention, the biological data of the HSA-doxorubicin conjugate A-DOXO-HYD-C are presented.

[0089] In the "RENCA" (renal cell carcinoma) model, doxorubicin and the conjugate A-DOXO-HYD-C according to the invention were compared with each other with respect to

antitumoral action at approximately equitoxic dose (intravenous therapy, 10 days after injection of roughly 1 million renal carcinoma cells into the left kidney).

[0090] Animals: Balb/c mice, female; tumor: RENCA, renal cell carcinoma; therapy: day (d) 10, 14, 18, 21 intravenous (i.v.); end of trial: d 25.

[0091] The results of these studies are summarized in Table 2.

Table 2

Number of mice	Substance	Dose (mg/kg/inj.)	Mortal- ity (d)	Average loss of body weight (%), d 1 to 25
10	Control		2	-14
10	Albumin control	4 x 1.4 g	1	-16
10	Doxorubicin (doxo)	4 x 6 mg/kg	1	-21
10	A-DOXO-HYD-C	4 x 12 mg/kg	0	-18

[0092] The dose is relative to the quantity of doxorubicin present. The dosages of doxorubicin and A-DOXO-HYD-C are approximately equitoxic (see loss of body weight in Table 2).

[0093] The results of this experiment are, further, graphically illustrated in Fig. 3 with respect to the weights and volumes of the kidneys and renal tumors (Fig. 3A) and the

lung weights and the number of pulmonary metastases (Fig. 3B).

A-DOXO-HYD-C shows a very good antitumoral effectiveness and brings about a complete remission in all animals.

Macroscopically visible pulmonary metastases could be observed in only one animal (Fig. 3B). In the group treated with doxorubicin, plainly visible renal tumors were observed in all animals (Fig. 3A); that is, in contrast, no complete remissions were brought about at the optimal dose of doxorubicin (body weight loss -21% (d 1 to 25); 1 animal died). Furthermore, the number of pulmonary metastases was on average some 100 metastases per mouse in the mice treated with free doxorubicin (Fig. 3B).

34 AMDT

August 27, 2001

Müller-Boré & Partner

Official File Number: PCT/EP 00/05254

Applicant: KTB Tumorforschungsgesellschaft mbH

CARRIER-DRUG CONJUGATE

Our File Number: K 2682 - py/js

Claims

1. Carrier-drug conjugate made up of a carrier, which contains a polypeptide sequence having one or a plurality of reducible cysteine groups, and a drug, which contains a pharmaceutically and/or diagnostically active substance, a spacer molecule, and a thiol-binding group, the spacer molecule and/or the linkage between the pharmaceutically and/or diagnostically active substance and the spacer molecule and/or the linkage between the thiol-binding group and the spacer molecule being cleavable hydrolytically and/or in pH-dependent fashion and/or enzymatically, and more than 0.7 mol of drug per mol of reducible cysteine group being bound to the

cysteine group of the carrier via the thiol-binding group.

2. Conjugate according to Claim 1, in which the carrier is native or recombinant albumin.

3. Conjugate according to Claim 1 or 2, in which the spacer molecule and/or the linkage contains at least one peptide bond.

4. Conjugate according to Claim 3, in which the peptide bond lies within a peptide sequence that contains at least one cleavage sequence of a protease.

5. Conjugate according to one of Claims 1 to 4, in which the spacer molecule and/or the linkage contains at least one acid-labile bond.

6. Conjugate according to one of Claims 1 to 5, in which the pharmaceutically active substance is a cytostatic, a cytokine, an immunosuppressant, an

antirheumatic, an antiphlogistic, an antibiotic, an analgesic, a virostatic or an antimycotic.

7. Conjugate according to Claim 6, in which the cytostatic is selected from the group of the anthracyclines, the N-nitrosoureas, the alkylating agents, the purine antagonists or pyrimidine antagonists, the folic acid antagonists, the taxanes, the camptothecins, the podophyllotoxin derivatives, the Vinca alkaloids, the calicheamicins, the maytansinoids or the *cis*-configured platinum(II) complexes.

8. Conjugate according to one of Claims 1 to 7, in which the diagnostically active substance contains one or a plurality of radionuclides, one or a plurality of ligands containing radionuclides, one or a plurality of positron emitters, one or a plurality of NMR contrast media, one or a plurality of fluorescing

ART 34 ANDT

compound(s) or one or a plurality of contrast media in the near IR region.

9. Conjugate according to one of Claims 1 to 8, in which the thiol-binding group contains a maleinimide group, a haloacetamide group, a haloacetate group, a pyridyldithio group, a vinylcarbonyl group, an aziridine group, a disulfide group or an acetylene group, which are substituted if appropriate.

10. Conjugate according to one of Claims 1 to 19, in which the spacer molecule is made up of a substituted or unsubstituted, branched-chain or straight-chain aliphatic alkyl group with 1 to 12 carbon atoms and/or at least one substituted or unsubstituted aryl group and/or an aliphatic carbon ring with 3 to 12 carbon atoms.

11. Method for the preparation of the conjugate according to one of Claims 1 to 10, including

(i) treatment of the carrier with a reducing agent so

APR 34 AMDT

that more than 0.7 mol, preferably at least 0.9 mol, of cysteine SH groups is present in the carrier per mol of reducible cysteine group and (ii) coupling of the drug to the cysteine SH groups in the carrier via the thiol-binding group.

12. Method according to Claim 11, in which the reducing agent is dithiothreitol, dithioerythritol or mercaptoethanol.

13. Method according to Claim 11 or 12, in which the conjugate prepared exhibits a purity of more than 95%.

14. Medicament containing the conjugate according to one of Claims 1 to 10 and, if appropriate, a pharmaceutically compatible carrier and/or an auxiliary agent and/or a diluting agent.

15. Medicament according to Claim 14 for the treatment of cancer diseases, autoimmune diseases, acute or chronically inflammatory diseases and

ART 34 AMDT

Variable	Mean	SD	Min	Max
Age	38.5	10.5	25	55
Gender	Male			
Marital status	Married			
Education	High school			
Occupation	Teacher			
Income	1000			
Health status	Good			
Smoking status	Non-smoker			
Alcohol consumption	None			
Stress level	Low			
Sleep quality	Good			
Exercise frequency	Low			
Dietary habits	Healthy			
Family size	3			
Work hours	40			
Compliance	High			
Knowledge	Good			
Attitude	Positive			
Behavior	Healthy			
Self-efficacy	High			
Perceived barriers	Low			
Perceived benefits	High			
Subjective norms	High			
Facilitating conditions	High			
Performance expectancy	High			
Effort expectancy	High			
Interaction expectancy	High			
Trust	High			
Privacy	High			
Security	High			
Reliability	High			
Availability	High			
Usability	High			
Usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			
Perceived ease of use	High			
Perceived effort	Low			
Perceived risk	Low			
Perceived privacy	High			
Perceived security	High			
Perceived reliability	High			
Perceived availability	High			
Perceived usability	High			
Perceived usefulness	High			


6

1/4

Fig. 1A


RUN# 101 MAR 6. 1901. 23:50:55

AREA#	RT	AREA	TYPE	WIDTH	AREA#
4.461	746394	PV	.413	6.00296	
6.123	234060	VH	.366	1.90754	
6.894	11209792	IGHP	.271	92.00930	

TOTAL AREA=1.2270E+07
MUL FACTOR=1.0000E+00

2/4

Fig. 1B



STOP

3/4

Fig. 2A

t = 0 min





Fig. 2B

t = 30 min



WO 00/76550

PCT/EP00/05254

4/4

Fig. 3A





Fig. 3B



K 2892 - py

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

Attorney Docket
Number: 25048-20

DECLARATION: As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Carrier-Drug Conjugate
the specification of which:

☒ [X] is attached hereto.
☒ [X] was filed on _____ as PCT Application Number PCT/EP00/05254 and amended on 27 August 2001
(if applicable.)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application on which priority is claimed:

<u>(Number)</u>	<u>(Country)</u>	<u>(Filed (Day/Month/Year))</u>	<u>[X] Yes</u> <u>[] No</u>
<u>199 26 475.9</u>	<u>DE</u>	<u>(10/06/99)</u>	<input checked="" type="checkbox"/> [X] <input type="checkbox"/> []
<u>(Number)</u>	<u>(Country)</u>	<u>Filed (Day/Month/Year)</u>	<input type="checkbox"/> [] <input type="checkbox"/> []
<u>(Number)</u>	<u>(Country)</u>	<u>Filed (Day/Month/Year)</u>	<input type="checkbox"/> [] <input type="checkbox"/> []

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Application Serial No.)</u>	<u>(Filing Date)</u>
---------------------------------	----------------------	---------------------------------	----------------------

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status - patented, pending, abandoned)</u>
---------------------------------	----------------------	--

POWER OF ATTORNEY: I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Joseph T. Guy, Reg. No. 35,172; John B. Hardaway, III, Reg. No. 26,554; William Y. Klett, III, Reg. No. 41,903; Michael A. Mann, Reg. No. 32,825; J. Herbert O'Toole, Reg. No. 31,404; Timothy J. Slabouze, Reg. No. 47,949; Charles L. Schwab, Reg. No. 17,497; Oscar A. Towler, III, Reg. No. 33,803; Townsend M. Belser, Jr., Reg. No. 22,956.

SEND ALL CORRESPONDENCE TO: John B. Hardaway, III, NEXSEN PRUET JACOBS & POLLARD, LLC, P.O. Box 10107, Greenville, South Carolina, 29603 TELEPHONE NUMBER: (864) 370-2211.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR (given name, family name) Felix Kratz
Complete Post Office Address Zum Abtsweingarten 19, 79241 Ihringen, Germany
City and Country of Residence Ihringen, Germany Citizenship DE
Inventor's Signature [Signature] Date 17/12/2001